Publication | Closed Access

Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

Hematological MalignancyFlow CytometryComplementary ToolMedicineMixed-phenotype Acute LeukemiaMalignant Blood DisorderHematologyTreatment DecisionsPathologyMyeloid NeoplasiaCytometryCell TransplantationMolecular DiagnosticsOncologyRadiation OncologyCancer ResearchHealth Sciences